7-6-04

+

of Ifw

type a plus sign (+) inside this box  $\rightarrow$ 

PTO/SB/21 (05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/674,124 **Application Number** September 26, 2003 **Filing Date TRANSMITTAL** First Named Inventor **INOKO, HIDETOSHI FORM** Group Art Unit 1635 (to be used for all correspondence after initial filing) **Examiner Name** Not Yet Assigned Attorney Docket Number **ORIN-003CIP** Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) Fee Transmittal Form **Assignment Papers** After Allowance Communication (for an Application) to Group Fee Attached Drawing(s) Appeal Communication to Board of Appeals and Interferences Amendment / Reply Licensing-related Papers After Final Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Petition Affidavits/declaration(s) Proprietary Information Petition to Convert to a **Extension of Time Request Provisional Application** Status Letter **Express Abandonment Request** Power of Attorney, Revocation Change of Correspondence X **Information Disclosure Statement** Other Enclosure(s) (please Address identify below): SB08a Form **Terminal Disclaimer Postcard** Certified Copy of Priority Request for Refund **Documents** CD, Number of CD(s Response to Missing Parts/ Incomplete Application Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signing Attorney/Agent CAROL L. FRANCIS, 36,513 (Reg. No.) BOZICEVIC, FIELD & FRANCIS LLP Signature Date July 1, 2004

**EXPRESS MAIL LABEL NO. EV 333997176 US** 

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## BANKA MADE LES

## Express Mail No. EV 333997176 US

ALL	INFORMATION
DISC	CLOSURE STATEMENT

Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	ORIN-003CIP				
First Named Inventor	INOKO, HIDETOSHI				
Application Number	10/674,124				
Confirmation No.	2646				
Filing Date	September 26, 2003				
Group Art Unit	1635				
Examiner Name	Not Yet Assigned				
Title: "GENE MAPPING METHOD USING MICROSATELLITE GENETIC POLYMORPHISM					

Sir:

,

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

MARKERS"

All of the references identified herein were disclosed in parent application serial number 10/257,511 filed 3/7/2003 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. ORIN-003CIP may be charged thereon.

Date:

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Respectfully submitted,

BOXICEVIC, FLELD & FRANCIS LLP

By:

Carol L. Francis

Registration No. 86,513

PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/674,124 Application Number **INFORMATION DISCLOSURE** Filing Date September 26, 2003 STATEMENT BY APPLICANT INOKO, HIDETOSHI First Named Inventor Art Unit 1635 **Examiner Name** Not Yet Assigned (use as many sheets as necessary) ORIN-003CIP Sheet 1 2 **Attorney Docket Number** 

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	
111111111111111111111111111111111111111	110.	Number-Kind Code* (If known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
			<u> </u>			

		FOREIG	N PATENT DO	CUMENTS					
Examiner Initials'	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰			
		WO 94/25625	11/10/1994	The Johns Hopkins University					
		OTHER PRIOR ART—N	ION PATENT LI	TERATURE DOCUMENT	rs				
Examiner Initials*					••	T²			
TAMIYA, et al., "MHC Ryouiki to Kansen", Idenshi Igaku, vol. 3, no. 1, pgs. 54-62, 1999					2, 1999				
		TAMIYA, et al., "Genome tayousei kaiseki ni yoru shikkan kanjusei idenshi no mapping; SNP to micro satellite no hikaku", Molecular Medicine, vol. 37, no. 5, pgs. 526-531, April 25, 2000							
		OKA, et al., "Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene", Human Molecular Genetics, vol. 8, no. 12, pgs. 2165-2170, 1999							
KEICHO, et al., "Fine localization of a major disease-susceptibility locus for diffu Hum. Genet., vol. 66, pgs. 501-507, 2000.					e panfronchiolitis", Am. J.				
		KIMURA, et al., "Mapping of the HLA-linked genes controlling the susceptiblity to Takayasu's arthritis", International Journal of Cardiology, Vol. 75, pp. S1Q5-S110, 2000							
		MIZUKI, et al., "Localization of the Pathogenic Gene of Behget's Disease by Microsatellite Analysis AV of Three Different Populations", Invest. Ophthalmol Vis Sci. Vol. 41, No. 12, pp. 3702-3708, November, 2002							

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/674,124	
			URE	Filing Date	September 26, 2003	
	STATEMENT BY APPLICANT			First Named Inventor	INOKO, HIDETOSHI	
				_Art Unit	1635	
(use as many sheets as necessary)		Examiner Name	Not Yet Assigned			
Sheet	2	of	2	Attorney Docket Number	ORIN-003CIP	

MATSUZAKA, et al., "New polymorphic microsatellite markers in the human MHC class II region", Tissue Antigens, Vol. 56, pp. 492-500, 2000
OTA, et al., "A Second Susceptibility Gene for Developing Rheumatoid Arthritis in the Human MHC AX is Localized within a 70-kb Interval Telomeric of the TNF Genes in the HLA Class III Region", Genomics. Vol. 71, pp. 263-270, 2001
MIZUKI, et al., "Microsatellite Mapping of a Susceptible Locus Within the HLA Region for Beliefs Disease Using Jordanian Patients", Human Immunology., Vol. 62, pp. 186-190, 2001
MATSUZAKA, et al., "Identification of novel candidate genes in the diffuse panbronchiolitis critical region of the class I human MHC", Immunogenetics. Vol. 54, pp. 301-309, 2002
MATSUZAKA, et al., "Susceptibility locus for non-obstructive azoospermia is localized within the HLA-DR/DQ subregion: Primary role of DQBl*0604", Tissue Antigens. Vol. 60, pp. 53-63, 2002
 NIIZEKI, et al., "Polymorphisms in the TNF region confer susceptibility to UVB-induced impairment of contact hypersensitivity induction in mice and humans", Methods, Vol. 28, pp. 46-54, 2002
OKA, et al., "Identification of psoriasis vulgaris-susceptible gene within HLA class I antigen", The 22 <sup>nd</sup> Annual meeting Pf MBSJ, IP-1334, November 22, 1999

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.